comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 16:27:41 - browse：675

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Medtronic CEO on promising devices for diabetes, hypertension

focus

hotspot

WSS

Chimpanzees, like humans and whales, get menopause: Study

Traditional Chinese medicine benefits explored in new JAMA study

Altering the blood type of lungs raises potential for universal organs for transplants

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Cassava reveals details — and problems — with Alzheimer's study

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Moonlake's readout produced a cash windfall. Risks remain

How to fix the rural physician shortage in the U.S.

Duchenne breakthrough therapy leaves behind pioneering families

Reanimated hearts work just as well for transplants, study finds

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Novo pauses ads for weight loss drug Wegovy amid demand

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Medicare proposal to cover medical devices draws a mixed reaction

CDC recommends rationing of RSV shot due to shortages

knowledge

Biogen nominates mother of director’s child to replace him on board

Meta's Zuckerberg and Chan on track to put $50 billion into science

Traditional Chinese medicine benefits explored in new JAMA study

WHO may add ‘noma' to its list of neglected tropical diseases

FDA has safety concerns on CRISPR

Patients, doctors are clashing about side effects of hormonal birth control

explore

focus

hotspot

hotspot